General Newsroom Hero 1920x480 (4:1)
Our Work

Latham & Watkins Advises the Underwriters in Rocket Pharmaceuticals’ Upsized Public Offering

December 10, 2020
A capital markets team advises the underwriters in the biotechnology company’s offering.

Rocket Pharmaceuticals, Inc. (Rocket), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, has announced the pricing of an upsized underwritten public offering of 4,642,858 shares of its common stock at a public offering price of US$56.00 per share. The gross proceeds to Rocket from the offering are expected to be approximately US$260 million, before deducting the underwriting discounts and commissions and other offering expenses. Rocket has granted the underwriters a 30-day option to purchase up to an additional 696,428 shares of its common stock. 

Latham & Watkins LLP represents the underwriters in the offering with a capital markets team led by New York partner Nathan Ajiashvili, with associates Taylor Stevens, Andrew Weitzel, and Egzon Sulejmani.